Two-Pronged attack tested for stubborn skin cancer
NCT ID NCT05846724
Summary
This study aimed to test a combination of two drugs, pembrolizumab and lenvatinib, for adults with classic Kaposi sarcoma that had come back or stopped responding to prior chemotherapy. The goal was to see if this two-drug approach could shrink tumors and control the disease better than standard chemotherapy options. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KAPOSI SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.